Author/Editor		Lavrič, Alenka; Drnovšek-Olup, Brigita
Title		Učinek podvezničnega bevacizumaba na pterigij
Translated title		Efficiency of subconjunctival bevacizumab on pterygium
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 81, št. Suppl
Publication year		2012
Volume		str. I-83-8
Language		slo
Abstract		Background: To evaluate the effect and complications of subconjunctival bevacizumab (Avastin Ž) on primary and recurrent pterygium. Methods: This prospective study included sixteen patients with pterygium, who received subconjunctival injection of bevacizumab (1.25 mg/0,1 mL). Digital photographywas used to evaluate vascularization of pterygium at 1 week, 1 month and 6 months after injection. Results: Sixteen patients (9 men and 7 women), aged between 41 and 74 years, with pterygium were included in the study. The pterygium was primary in nine patients and recurrent in seven patients. A rapid regression of vascularisation of pterygium was noted one week after treatment in all patients treated with bevacizumab. The recurrence was observed in two patients 1 month and in ten patients 6 months after injection. No change of visual acuity was noted and no systemic or ocular adverse events were observed. Conclusions: Subconjunctival bevacizumab (AvastinŽ) was safe and effective in providing a short-term regression of conjunctival vessels in the pterygial bed.
Summary		Izhodišča: Oceniti učinek in zaplete podvezničnega bevacizumaba (AvastinŽ) na primarni in ponavljajoči se pterigij. Metode: Prospektivna študija je vključevala 16 bolnikov s pterigijem, ki so prejeli injekcijo bevacizumaba podočesno veznico (1,25 mg/0,1 mL). Ožiljenost pterigija 1 teden, 1 mesec in 6mesecev po injekciji smo ocenili s primerjavo digitalnih fotografij. Rezultati: V študijo je bilo vključenih 16 bolnikov s pterigijem (9 moških in 7 žensk), starih med 41 in 74 let. Pterigij je bil primaren pri devetih bolnikih in ponavljajoči se pri 7 bolnikih. Pri vseh bolnikih, zdravljenih z bevacizumabom, smo opazili hitro pojenjanje ožiljenosti pterigija en teden po zdravljenju. Ponovitev vaskularizacije smo opazili pri dveh bolnikih 1 mesec in pri desetih bolnikih 6 mesecev po injekciji. Sprememb v vidni ostrini, sistemskih ali očesnih škodljivih učinkov nismo opazili. Zaključki: Podveznični bevacizumab (AvastinŽ) je bil varen in učinkovit pri kratkotrajni regresiji vezničnih žilic v pterigiju.